Literature DB >> 2870901

Metabolism of isotretinoin. Biliary excretion of isotretinoin glucuronide in the rat.

S Meloche, J G Besner.   

Abstract

The biliary metabolites of isotretinoin were examined after iv administration of 4-20-mg/kg doses to vitamin A-normal bile duct-cannulated rats. Analysis of bile by reverse phase high performance liquid chromatography showed that injection of isotretinoin is followed by a rapid excretion of metabolites in bile. Isotretinoin glucuronide was identified as the major metabolite in bile. A specific high performance liquid chromatography method based on the assay of generated isotretinoin in beta-glucuronidase-treated bile was developed for the determination of isotretinoin glucuronide in bile samples. The excretion rate of isotretinoin glucuronide increased rapidly to reach a maximum 55 min after dosing and then declined exponentially. After 330 min of collection, biliary excretion of isotretinoin glucuronide was almost complete, and the metabolite accounted for 34.8-37.9% of the dose. These results indicate that conjugation with glucuronic acid represents a major pathway for the metabolism of pharmacological doses of isotretinoin. The maximum excretion rate of isotretinoin glucuronide in bile increased in a linear manner with the dose of isotretinoin, and no delay was observed after the larger doses. These data suggest that glucuronidation and biliary excretion are not saturated at high pharmacological doses of isotretinoin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2870901

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  2 in total

1.  Chemical synthesis and growth-promoting activity of all-trans-retinyl beta-D-glucuronide.

Authors:  A B Barua; J A Olson
Journal:  Biochem J       Date:  1987-05-15       Impact factor: 3.857

2.  Hepatotoxicity of isotretinoin in patients with acne and Gilbert's syndrome: a comparative study.

Authors:  Pablo Fernández-Crehuet; José Luis Fernández-Crehuet; Mohamed Farouk Allam; Rafael Fernández-Crehuet Navajas
Journal:  BMJ Open       Date:  2014-03-20       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.